NDATOPICALLOTION
Approved
Mar 2010
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
20
Data completeness
6/8 — Strong
DIFFERIN (adapalene) by Galderma is mechanism of action: adapalene acts on retinoid receptors. Approved for acne vulgaris, photoaging. First approved in 2010.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DIFFERIN (adapalene) is a topical retinoid lotion approved for acne vulgaris and photoaging indications. It works by binding to retinoic acid nuclear receptors to normalize follicular epithelial cell differentiation, reducing microcomedone formation and cutaneous inflammation.
$0.094MPart D
LOE ApproachingDeclining
2.1 years to LOESmall Part D footprint signals niche brand; near-term LOE (2028) will compress team size and shift focus to generic transition and pipeline backfill.
Mechanism of Action
Mechanism of Action: Adapalene acts on retinoid receptors. Biochemical and pharmacological profile studies have demonstrated that adapalene is a modulator of cellular differentiation, keratinization, and inflammatory processes all of which represent important features in the pathology of acne…
Indications (2)
Worked on DIFFERIN at Galderma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.